Latitude Tissue-Free MRD
Use
Latitude™ is a tissue-free, blood-based residual disease test (MRD) specifically designed for colorectal cancer (CRC) patients. It provides crucial information about a patient’s disease status post-operatively and during post-definitive treatment surveillance. The test offers high sensitivity and specificity for detecting residual disease in CRC patients. In clinical studies, Latitude™ helped identify which patients could benefit from adjuvant chemotherapy (ACT) and provided early indication of relapse, illustrating a median lead time of 4.6 months before radiographic relapse.
Special Instructions
Not provided.
Limitations
The sensitivity of the Latitude™ test varies according to the time of testing. Post-operative sensitivity is reported at 58%, while longitudinal sensitivity during surveillance is higher at 84% and 87% for colon cancer specifically. The specificity of the test is reported to be 97%, which may have implications for interpreting results, especially in relation to treatment decisions.
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
Result Turnaround Time
0 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Other tests from different labs that may be relevant